Nuvig Therapeutics, a Redwood City, CA-based developer of therapies that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function, raised $47M in Series A funding.
The round was led by Novo Holdings A/S and Platanus, with participation from Bristol Myers Squibb, Digitalis Ventures, and Mission BioCapital.
The company intends to use the funds to expand its development efforts.
Led by Pamela Conley, Ph.D., Chief Executive Officer, Nuvig Therapeutics offers protein therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Nuvig is building a pipeline of immune therapeutics for chronic inflammatory and autoimmune diseases.
FinSMEs
12/05/2022